Sujal Shah Buys 5,000 Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) Stock

CymaBay Therapeutics Inc (NASDAQ:CBAY) CEO Sujal Shah acquired 5,000 shares of the stock in a transaction that occurred on Thursday, October 10th. The stock was acquired at an average price of $4.30 per share, for a total transaction of $21,500.00. Following the transaction, the chief executive officer now directly owns 120,000 shares of the company’s stock, valued at approximately $516,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Sujal Shah also recently made the following trade(s):

  • On Friday, September 20th, Sujal Shah acquired 1,900 shares of CymaBay Therapeutics stock. The stock was acquired at an average price of $5.50 per share, for a total transaction of $10,450.00.
  • On Monday, September 23rd, Sujal Shah acquired 5,000 shares of CymaBay Therapeutics stock. The stock was acquired at an average price of $5.53 per share, for a total transaction of $27,650.00.

NASDAQ CBAY opened at $4.68 on Wednesday. The stock’s 50-day simple moving average is $5.44 and its two-hundred day simple moving average is $8.47. CymaBay Therapeutics Inc has a twelve month low of $4.23 and a twelve month high of $14.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 16.20 and a current ratio of 16.20.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.02. Research analysts predict that CymaBay Therapeutics Inc will post -1.47 EPS for the current year.

CBAY has been the topic of a number of recent analyst reports. BidaskClub downgraded CymaBay Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 30th. ValuEngine downgraded CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 10th. Cantor Fitzgerald set a $20.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Zacks Investment Research upgraded CymaBay Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research report on Tuesday, October 8th. Finally, Stifel Nicolaus assumed coverage on CymaBay Therapeutics in a research report on Monday, June 24th. They set a “buy” rating and a $14.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the stock. CymaBay Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $13.25.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CBAY. BlackRock Inc. increased its holdings in shares of CymaBay Therapeutics by 9.8% in the second quarter. BlackRock Inc. now owns 5,530,692 shares of the biopharmaceutical company’s stock worth $39,600,000 after buying an additional 493,662 shares during the period. Sphera Funds Management LTD. purchased a new position in shares of CymaBay Therapeutics in the first quarter worth about $4,589,000. Nuveen Asset Management LLC purchased a new position in shares of CymaBay Therapeutics in the second quarter worth about $2,463,000. University of Notre Dame DU Lac purchased a new position in shares of CymaBay Therapeutics in the second quarter worth about $2,043,000. Finally, Vanguard Group Inc. increased its holdings in shares of CymaBay Therapeutics by 6.8% in the second quarter. Vanguard Group Inc. now owns 3,559,875 shares of the biopharmaceutical company’s stock worth $25,488,000 after buying an additional 226,906 shares during the period. Institutional investors and hedge funds own 98.68% of the company’s stock.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Featured Article: How prevalent are 12b-1 fees?

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.